Literature DB >> 12041951

Diagnosis and management of patients with neuropsychiatric systemic lupus erythematosus (NPSLE).

David Hermosillo-Romo1, Robin L Brey.   

Abstract

Neuropsychiatric systemic lupus erythematosus (NPSLE) involves a wide range of focal and diffuse central and peripheral nervous system disorders and affects up to 75% of SLE patients. NPSLE can occur any time in the course of SLE, even during periods in which no SLE disease activity is detected, and is likely to be caused by multiple factors, including autoantibody production, microvasculopathy and pro-inflammatory cytokines. Central to the diagnosis of NPSLE is the question of whether the presenting neuropsychiatric symptoms are due to SLE-mediated organ dysfunction, infection, medication side-effects or metabolic abnormalities (e.g. uraemia), or are due to an unrelated condition. The diagnostic inference of NPSLE can be made only after these secondary causes have been excluded. There is no one single diagnostic tool specific to NPSLE, and clinical diagnostic impressions must be based on the combined use of immunoserological testing, functional and/or structural neuroimaging and standardized neurological, rheumatological, psychiatric and neuropsychological assessments. The management of NPSLE includes symptomatic and/or immunosuppressive treatment strategies depending on the specific presenting neuropsychiatric symptoms and whether these occur in the setting of an SLE disease activity flare. Copyright 2002 Elsevier Science Ltd.

Entities:  

Mesh:

Year:  2002        PMID: 12041951     DOI: 10.1053/berh.2001.0223

Source DB:  PubMed          Journal:  Best Pract Res Clin Rheumatol        ISSN: 1521-6942            Impact factor:   4.098


  12 in total

1.  Jaw Dystonia and Reversible Basal Ganglia Changes as an Initial Presentation of Systemic Lupus Erythematosus.

Authors:  Meghan Romba; Yujie Wang; Shu-Ching Hu; Sandeep Khot
Journal:  Neurohospitalist       Date:  2017-03-10

Review 2.  Immunological aetiology of major psychiatric disorders: evidence and therapeutic implications.

Authors:  Barbara Sperner-Unterweger
Journal:  Drugs       Date:  2005       Impact factor: 9.546

3.  Accuracy of cerebrospinal fluid IL-6 testing for diagnosis of lupus psychosis. A multicenter retrospective study.

Authors:  Shunsei Hirohata; Yoshinori Kanai; Akiko Mitsuo; Yoshiaki Tokano; Hiroshi Hashimoto
Journal:  Clin Rheumatol       Date:  2009-07-12       Impact factor: 2.980

Review 4.  Tailored treatment strategies and future directions in systemic lupus erythematosus.

Authors:  Dionysis Nikolopoulos; Lampros Fotis; Ourania Gioti; Antonis Fanouriakis
Journal:  Rheumatol Int       Date:  2022-04-21       Impact factor: 3.580

Review 5.  Neuropsychiatric involvement in systemic lupus erythematosus.

Authors:  David Hermosillo-Romo; Robin L Brey
Journal:  Curr Rheumatol Rep       Date:  2002-08       Impact factor: 4.592

6.  Reversible dementia in systemic lupus erythematosus without antiphospholipid antibodies or cerebral infarction.

Authors:  S I Lee; H S Jeon; W H Yoo
Journal:  Rheumatol Int       Date:  2004-02-28       Impact factor: 2.631

7.  Depression is an early disease manifestation in lupus-prone MRL/lpr mice.

Authors:  Hua-Xin Gao; Sean R Campbell; Min-Hui Cui; Pu Zong; Jong Hee-Hwang; Maria Gulinello; Chaim Putterman
Journal:  J Neuroimmunol       Date:  2009-01-03       Impact factor: 3.478

8.  Depressive and Anxiety Disorders in Systemic Lupus Erythematosus Patients without Major Neuropsychiatric Manifestations.

Authors:  Ru Bai; Shuang Liu; Yueyin Zhao; Yuqi Cheng; Shu Li; Aiyun Lai; Zhongqi Xie; Xinyu Xu; Zhaoping Lu; Jian Xu
Journal:  J Immunol Res       Date:  2016-09-26       Impact factor: 4.818

9.  Determinants and protective associations of the lupus low disease activity state in a prospective Chinese cohort.

Authors:  Yanjie Hao; Shereen Oon; Lanlan Ji; Dai Gao; Yong Fan; Yan Geng; Xiaohui Zhang; Guangtao Li; Eric F Morand; Mandana Nikpour; ZhuoLi Zhang
Journal:  Clin Rheumatol       Date:  2021-09-30       Impact factor: 2.980

Review 10.  Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives.

Authors:  César Magro-Checa; Elisabeth J Zirkzee; Tom W Huizinga; Gerda M Steup-Beekman
Journal:  Drugs       Date:  2016-03       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.